SECONDARY HYPERPARATHYROIDISM TREATMENT MARKET ANALYSIS

Secondary Hyperparathyroidism Treatment MarketSize and Trends

Secondary Hyperparathyroidism Treatment Market: Market Dynamics

Rising incidence of chronic kidney diseases is one of the major factors responsible for growth of the global secondary hyperparathyroidism treatment market. According to Centers of Disease Control & Prevention (CDC) 2017, 30 million people or 15% of the U.S. adults are estimated to have chronic kidney disease, out of which 48% suffer severely with reduced kidney function, however, are not aware of having a CKD. Moreover, according to the National Kidney Foundation 2016, 10% of the population across the world are affected with chronic kidney diseases. Additionally, extensive research in the field of nephrology to come up with new drugs and therapies for treatment of secondary hyperparathyroidism is responsible for fueling growth of the market. For instance, Sanofi SA’s Hectorol capsules is undergoing Phase 3 clinical trials to evaluate the safety and efficacy of this medication in reducing the level of secondary hyperparathyroidism in pediatric patients with chronic kidney diseases at stage 3 and 4. The drug is expected to complete its study in December 2017, and be commercially available in market. However, side effects usually associated with secondary hyperparathyroidism treatment such as muscle spasm, diarrhea, and vomiting may cause hindrance to growth of the market.